Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Technology Transfers To Least-Developed Countries Often Not An Option - IFPMA Report

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - The transfer of technology developed by high-end research-based pharmaceutical companies to operations in developing countries is increasingly common, but rarely simple

You may also be interested in...



U.S. AIDS Assistance Unable To Transfer To Local Ownership In Emerging Markets Like Africa

PEPFAR-supported countries are not ready to take over their AIDS programs as projected, in part because of the financial crisis.

BMS Launches Pilot Program With WHO In Five African Countries

Bristol-Myers Squibb is scaling up its community-based tuberculosis interventions to support HIV-positive populations in Africa. The U.S. drug maker's charity wing, Bristol-Myers Squibb Foundation signed a collaboration agreement with the World Health Organization and committed $1.2 million to help develop a global guidance involving national TB programs to fight tuberculosis

BMS Launches Pilot Program With WHO In Five African Countries

Bristol-Myers Squibb is scaling up its community-based tuberculosis interventions to support HIV-positive populations in Africa. The U.S. drug maker's charity wing, Bristol-Myers Squibb Foundation signed a collaboration agreement with the World Health Organization and committed $1.2 million to help develop a global guidance involving national TB programs to fight tuberculosis

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel